In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 151 to 160 of 318

TitleTypeExpected publication date
Lifileucel for previously treated unresectable or metastatic melanoma ID3863Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]Technology appraisal guidanceTBC
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor [ID6434]Technology appraisal guidanceTBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340Technology appraisal guidanceTBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer PD [ID6526]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All